AtriCure (ATRC) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $58.97 -0.56%
EPS Growth %: -300.0%
Financial Fact:
Revenue: 38.34M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -300.0%
Financial Fact:
Revenue: 38.34M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.08), $0.13 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $46.1 million versus the consensus estimate of $45.36 million.
2018 Financial Guidance
Management projects 2018 revenue of approximately $190 million to $196 million. Adjusted EBITDA, a non-GAAP measure, is projected to be positive for 2018.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
